Please login to view this media
- Talk
- 22/09/2021
- UK
Intravenous Tranexamic Acid given at Femoral Fragility Fracture Surgery reduces blood transfusion requirements four-fold
Description
This transcript presents a detailed presentation by Matilda Powell-Bownes from Edinburgh Royal Infirmary discussing the use of Tranexamic Acid (TXA) in patients undergoing surgery for femoral fragility fractures. She explains how TXA functions as a clot-stabilizing drug, notes its current use in primary arthroplasty, and addresses the surrounding debates about its application in femoral injuries.
The study aimed to ascertain if administering 1 gram of TXA during surgery would influence postoperative blood transfusion requirements. The four-month study included patients with femoral fragility fractures, excluding those who required blood transfusions during or after surgery. Powell-Bownes notes the study's observational nature, classifying it as case-control without randomization.
Results showed significant reductions in postoperative blood loss and a 74% decrease in the need for blood transfusions among those receiving TXA. Complications, including acute kidney injury and myocardial infarctions, were noted but deemed not statistically significant. Powell-Bownes emphasizes the cost-effectiveness of TXA, suggesting substantial savings compared to the cost of blood transfusions.
The discussion also includes questions from Donald Campbell regarding the transfusion criteria and the broader implications for future randomized controlled trials, recognizing the ongoing concerns regarding venous thromboembolism (VTE) risks associated with TXA. Overall, the presentation concludes with a strong endorsement for the routine use of TXA in treating femoral fragility fractures, advocating for its benefits and cost-saving potential.